Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer (NSCLC): a randomised trial of chemotherapy versus symptomatic treatment only in patients not suitable for radical radiotherapy
- Conditions
- ung (non-small cell) cancerCancerLung cancer
- Registration Number
- ISRCTN38657696
- Lead Sponsor
- Cancer Research UK (CRUK) (UK)
- Brief Summary
1999 presumed results in https://www.ncbi.nlm.nih.gov/pubmed/10506617 (added 30/10/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 0
1. Age 75 years or under
2. Histologically or cytologically proven non-small cell lung cancer, ie adeno-squamous or large cell carcinoma
3. Clinically or radiologically evaluable disease
4. Inoperable, but clinically limited stage disease
5. World Health Organisation (WHO) performance status of 0-2
6. No previous chemotherapy or radiotherapy
7. No cerebral metastases, spinal cord compression or symptomatic superior vena cava obstruction
8. Normal renal function
9. No other previous or concurrent malignancy, except cone biopsied carcinoma in-situ of the cervix and adequately treated basal cell carcinoma of the skin
10. No indication that protocol treatment would exacerbate a serious pre-existing medical condition
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration